MA47420A - Composés inhibiteurs d'oga - Google Patents

Composés inhibiteurs d'oga

Info

Publication number
MA47420A
MA47420A MA047420A MA47420A MA47420A MA 47420 A MA47420 A MA 47420A MA 047420 A MA047420 A MA 047420A MA 47420 A MA47420 A MA 47420A MA 47420 A MA47420 A MA 47420A
Authority
MA
Morocco
Prior art keywords
inhibitor compounds
oga inhibitor
oga
compounds
inhibitor
Prior art date
Application number
MA047420A
Other languages
English (en)
Inventor
José Manuel Bartolomé-Nebreda
Viturro Carlos Manuel Martinez
Andrés Avelino Trabanco-Suárez
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA47420A publication Critical patent/MA47420A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA047420A 2017-02-06 2018-02-06 Composés inhibiteurs d'oga MA47420A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17154751 2017-02-06

Publications (1)

Publication Number Publication Date
MA47420A true MA47420A (fr) 2019-12-11

Family

ID=57965815

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047420A MA47420A (fr) 2017-02-06 2018-02-06 Composés inhibiteurs d'oga

Country Status (8)

Country Link
US (1) US20200048267A1 (fr)
EP (1) EP3577121A1 (fr)
JP (1) JP2020506940A (fr)
CN (1) CN110267961A (fr)
AU (1) AU2018216040A1 (fr)
CA (1) CA3045816A1 (fr)
MA (1) MA47420A (fr)
WO (1) WO2018141984A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX381417B (es) 2014-08-28 2025-03-12 Asceneuron Sa Inhibidores de glucosidasa.
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
JP2019506430A (ja) 2016-02-25 2019-03-07 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
JP6971999B2 (ja) 2016-02-25 2021-11-24 エースニューロン・ソシエテ・アノニム ピペラジン誘導体の酸付加塩
CN108884077A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
AU2018223192A1 (en) * 2017-02-27 2019-06-20 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as OGA inhibitors
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039029A1 (fr) * 2018-08-22 2020-02-27 Asceneuron S. A. Composés spiro utilisés en tant qu'inhibiteurs de glycosidases
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
CA3110032A1 (fr) 2018-08-22 2020-02-27 Asceneuron S.A. Sels d'addition d'acide succinate et fumarate de derives de piperazine utiles en tant qu'inhibiteurs de glycosidase
TW202130643A (zh) * 2019-10-29 2021-08-16 美商百健Ｍａ公司 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑
WO2025247394A1 (fr) * 2024-05-31 2025-12-04 纽欧申医药(上海)有限公司 Composé hétérocyclique contenant de l'azote, composition pharmaceutique de celui-ci et utilisation associée
CN121405694A (zh) * 2024-07-26 2026-01-27 浙江同源康医药股份有限公司 Oga抑制剂及其应用
CN119569746B (zh) * 2025-02-06 2025-05-13 纽欧申医药(上海)有限公司 含氮杂环化合物、其药物组合物及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1519939E (pt) * 2002-07-05 2010-02-10 Targacept Inc Compostos n-arildiazaspirocíclicos e métodos para a sua preparação e utilização
AU2009261248A1 (en) * 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
TW201030007A (en) * 2009-02-06 2010-08-16 Gruenenthal Gmbh Substituted spiro-amides as b1r modulators
US20120010186A1 (en) * 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2773207B1 (fr) 2011-10-31 2018-03-07 Merck Sharp & Dohme Corp. Aminopyrimidinones en tant qu'inhibiteurs de kinases associées au récepteur de l'interleukine
WO2014023723A1 (fr) 2012-08-08 2014-02-13 Novartis Ag Azines substituées comme pesticides
WO2016015604A1 (fr) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations
MX381417B (es) * 2014-08-28 2025-03-12 Asceneuron Sa Inhibidores de glucosidasa.
MD3316969T2 (ro) * 2015-07-02 2022-07-31 Janssen Sciences Ireland Unlimited Co Compuși antibacterieni
US10323038B2 (en) * 2015-11-20 2019-06-18 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2017087858A1 (fr) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
WO2018026371A1 (fr) * 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Inhibiteurs doubles de nav1.2/5ht2a pour traiter des troubles du snc

Also Published As

Publication number Publication date
AU2018216040A1 (en) 2019-06-20
WO2018141984A1 (fr) 2018-08-09
CA3045816A1 (fr) 2018-08-09
EP3577121A1 (fr) 2019-12-11
US20200048267A1 (en) 2020-02-13
JP2020506940A (ja) 2020-03-05
CN110267961A (zh) 2019-09-20

Similar Documents

Publication Publication Date Title
MA52939A (fr) Composés inhibiteurs d'oga
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
MA52942A (fr) Composés inhibiteurs d'oga
MA47576A (fr) Composés inhibiteurs d'oga bicyclique
EP3720430A4 (fr) Composés benzocarbonyle
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52948A (fr) Composés
EP3691623A4 (fr) Composés de benzosulfonyle
EP3464275A4 (fr) Composés inhibiteurs de l'egfr
EP3737672A4 (fr) Composés benzamide
MA51669A (fr) Composés
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA44725A (fr) Formulations d'un inhibiteur de lsd1
MA53003A (fr) Composés
MA49006A (fr) Inhibiteurs d'ip6k
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3562487A4 (fr) Composés inhibiteurs des métalloenzymes
EP3728289A4 (fr) Composés optimisés
EP3464336A4 (fr) Composés
MA52946A (fr) Composés
LT3867247T (lt) Naujieji junginiai
EP3808747A4 (fr) Composé d'imidazopyridinone
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
IL269695A (en) Compounds useful as inhibitors of alcat 1
HUE056928T2 (hu) Új vegyületek